# Panolos Bioscience Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/panolos-bioscience-co

- Industry: Biotechnology
- Headquarters: South Korea
- Website: www.panolos.com
- Total disclosed funding: $18M
- Latest round: Series A (May 17, 2021)
- Investors on record: 5

## About

Founded in 2019 and based in South Korea, Panolos Bioscience Co., Ltd. operates as a drug development company that develops biopharmaceutical solutions. The company was founded by its CEO, Hyeseong Lim. In May 2021, Panolos Bioscience Co., Ltd. raised KRW 20 billion in series A funding from DC Chemical, Cloudib Investment, JL PARTNERS, KClavis Investment, and UTC Investment.

Panolos Bioscience provides a biotherapeutics platform, which is an anti-angiogenesis-based artifact re-targeting tri-specifics (aART) platform that develops protein structure-based drugs for the treatment of cancer and rare diseases. The firm’s oncology pipeline portfolio includes PB101, an anti-cancer drug candidate that inhibits the growth of tumor cells by blocking angiogenic factors; PB102; PB201; PB203, an anti-PD-L1 module that targets PD-L1 cancer cells; and PB301.

## Funding rounds

- Series A, May 17, 2021, $18M — UTC Investment, JL Partners, Cloud IB Investment, KClavis Investment, OCI

## Investors

- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series A
- JL Partners (https://capitalatlas.ai/funds/jl-partners) — Series A
- Cloud IB Investment (https://capitalatlas.ai/funds/cloud-ib-investment) — Series A
- KClavis Investment (https://capitalatlas.ai/funds/kclavis-investment) — Series A
- OCI — Series A